These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38692011)

  • 1. Pirfenidone and nintedanib exert additive antifibrotic effects by the SPP1-AKT pathway in macrophages and fibroblasts.
    Meng C; Fan G; Liu J; Tao N; Sun T
    Biochem Biophys Res Commun; 2024 Jul; 716():150020. PubMed ID: 38692011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SPP1 induces idiopathic pulmonary fibrosis and NSCLC progression via the PI3K/Akt/mTOR pathway.
    Yue B; Xiong D; Chen J; Yang X; Zhao J; Shao J; Wei D; Gao F; Huang M; Chen J
    Respir Res; 2024 Oct; 25(1):362. PubMed ID: 39369217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib.
    Zhang Y; Jones KD; Achtar-Zadeh N; Green G; Kukreja J; Xu B; Wolters PJ
    Histopathology; 2019 Jan; 74(2):341-349. PubMed ID: 30152895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
    Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
    BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects.
    Overed-Sayer C; Miranda E; Dunmore R; Liarte Marin E; Beloki L; Rassl D; Parfrey H; Carruthers A; Chahboub A; Koch S; Güler-Gane G; Kuziora M; Lewis A; Murray L; May R; Clarke D
    Thorax; 2020 Sep; 75(9):754-763. PubMed ID: 32709610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
    Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
    Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tubastatin ameliorates pulmonary fibrosis by targeting the TGFβ-PI3K-Akt pathway.
    Saito S; Zhuang Y; Shan B; Danchuk S; Luo F; Korfei M; Guenther A; Lasky JA
    PLoS One; 2017; 12(10):e0186615. PubMed ID: 29045477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual inhibition of α
    Decaris ML; Schaub JR; Chen C; Cha J; Lee GG; Rexhepaj M; Ho SS; Rao V; Marlow MM; Kotak P; Budi EH; Hooi L; Wu J; Fridlib M; Martin SP; Huang S; Chen M; Muñoz M; Hom TF; Wolters PJ; Desai TJ; Rock F; Leftheris K; Morgans DJ; Lepist EI; Andre P; Lefebvre EA; Turner SM
    Respir Res; 2021 Oct; 22(1):265. PubMed ID: 34666752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nintedanib Ameliorates Bleomycin-Induced Pulmonary Fibrosis, Inflammation, Apoptosis, and Oxidative Stress by Modulating PI3K/Akt/mTOR Pathway in Mice.
    Pan L; Cheng Y; Yang W; Wu X; Zhu H; Hu M; Zhang Y; Zhang M
    Inflammation; 2023 Aug; 46(4):1531-1542. PubMed ID: 37160579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Antifibrotic Mechanism of Nintedanib and Pirfenidone. Inhibition of Collagen Fibril Assembly.
    Knüppel L; Ishikawa Y; Aichler M; Heinzelmann K; Hatz R; Behr J; Walch A; Bächinger HP; Eickelberg O; Staab-Weijnitz CA
    Am J Respir Cell Mol Biol; 2017 Jul; 57(1):77-90. PubMed ID: 28257580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ATP-induced fibrogenic pathway in circulating cells obtained by idiopathic pulmonary fibrotic (IPF) patients is not blocked by nintedanib and pirfenidone.
    Colarusso C; Falanga A; Di Caprio S; Terlizzi M; D'Andria E; Antonio M; Maiolino P; Sorrentino R
    Biomed Pharmacother; 2024 Jul; 176():116896. PubMed ID: 38876049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Micro-CT-assisted identification of the optimal time-window for antifibrotic treatment in a bleomycin mouse model of long-lasting pulmonary fibrosis.
    Buccardi M; Grandi A; Ferrini E; Buseghin D; Villetti G; Civelli M; Sverzellati N; Aliverti A; Pennati F; Stellari FF
    Sci Rep; 2024 Jun; 14(1):14792. PubMed ID: 38926490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis.
    Lehmann M; Buhl L; Alsafadi HN; Klee S; Hermann S; Mutze K; Ota C; Lindner M; Behr J; Hilgendorff A; Wagner DE; Königshoff M
    Respir Res; 2018 Sep; 19(1):175. PubMed ID: 30219058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis.
    Xie Y; Jiang H; Zhang Q; Mehrotra S; Abel PW; Toews ML; Wolff DW; Rennard S; Panettieri RA; Casale TB; Tu Y
    Respir Res; 2016 Aug; 17(1):103. PubMed ID: 27549302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis.
    Lehtonen ST; Veijola A; Karvonen H; Lappi-Blanco E; Sormunen R; Korpela S; Zagai U; Sköld MC; Kaarteenaho R
    Respir Res; 2016 Feb; 17():14. PubMed ID: 26846335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD148 Deficiency in Fibroblasts Promotes the Development of Pulmonary Fibrosis.
    Tsoyi K; Liang X; De Rossi G; Ryter SW; Xiong K; Chu SG; Liu X; Ith B; Celada LJ; Romero F; Robertson MJ; Esposito AJ; Poli S; El-Chemaly S; Perrella MA; Shi Y; Whiteford J; Rosas IO
    Am J Respir Crit Care Med; 2021 Aug; 204(3):312-325. PubMed ID: 33784491
    [No Abstract]   [Full Text] [Related]  

  • 17. Incidence of acute exacerbation of idiopathic pulmonary fibrosis in patients receiving antifibrotic agents: Real-world experience.
    Isshiki T; Sakamoto S; Yamasaki A; Shimizu H; Miyoshi S; Nakamura Y; Homma S; Kishi K
    Respir Med; 2021 Oct; 187():106551. PubMed ID: 34343721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
    Takehara K; Koga Y; Hachisu Y; Utsugi M; Sawada Y; Saito Y; Yoshimi S; Yatomi M; Shin Y; Wakamatsu I; Umetsu K; Kouno S; Nakagawa J; Sunaga N; Maeno T; Hisada T
    Cells; 2022 Jan; 11(1):. PubMed ID: 35011705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated bioinformatics analysis identifies established and novel TGFβ1-regulated genes modulated by anti-fibrotic drugs.
    Wilson AC; Chiles J; Ashish S; Chanda D; Kumar PL; Mobley JA; Neptune ER; Thannickal VJ; McDonald MN
    Sci Rep; 2022 Feb; 12(1):3080. PubMed ID: 35197532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ESL attenuates BLM-induced IPF in mice: Dual mediation of the TLR4/NF-κB and TGF-β1/PI3K/Akt/FOXO3a pathways.
    Jia C; Yang M; Xiao G; Zeng Z; Li L; Li Y; Jiang J; Xu A; Qiu J; Tang R; Li D; Jia D; Xie C; Wu G; Cai D; Bi X
    Phytomedicine; 2024 Sep; 132():155545. PubMed ID: 38972238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.